Insight Molecular Diagnostics (IMDX) Cash from Operations (2015 - 2026)

Insight Molecular Diagnostics has disclosed Cash from Operations across 12 years of filings, most recently posting 7639000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 7639000.0, down 30.83% year-over-year; the trailing twelve-month figure through Mar 2026 was 23984000.0 (down 5.67% YoY), and the FY2025 annual result was 22184000.0, down 7.23% from the prior year.
• Cash from Operations came in at 7639000.0 for Q1 2026 at Insight Molecular Diagnostics, down from 5545000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 3769000.0 in Q3 2023 to a low of 13277000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 5978000.0 (2024), against an average of 7023823.53.
• Across the five-year window, Cash from Operations soared 66.93% in 2023 and plunged 52.45% in 2025, its largest moves.
• Insight Molecular Diagnostics' Cash from Operations stood at 9648000.0 in 2022, then jumped by 54.15% to 4424000.0 in 2023, then fell by 20.95% to 5351000.0 in 2024, then fell by 3.63% to 5545000.0 in 2025, then slumped by 37.76% to 7639000.0 in 2026.
• The last three Cash from Operations figures came in at 7639000.0 (Q1 2026), 5545000.0 (Q4 2025), and 4502000.0 (Q3 2025), per Business Quant data.